Browse
Submit Data
Databases
API
Help

Dataset Information

18 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.

ABSTRACT: Herein, we disclose a series of selective GluN2B negative allosteric modulators containing a 1H-pyrrolo[3,2-b]pyridine core. Lead optimization efforts included increasing brain penetration as well as decreasing cytochrome P450 inhibition and hERG channel binding. The series was also optimized to reduce metabolic turnover in human and rat. Compounds 9, 25, 30, and 34 have good in vitro GluN2B potency and good predicted absorption, but moderate to high projected clearance. They were assessed in vivo to determine their target engagement. All four compounds achieved >75% receptor occupancy after an oral dose of 10 mg/kg in rat. Compound 9 receptor occupancy was measured in a dose-response experiment, and its ED50 was found to be 2.0 mg/kg.

SUBMITTER: Chrovian CC

PROVIDER: S-EPMC6421534 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.

Chrovian Christa C CC Soyode-Johnson Akinola A Wall Jessica L JL Rech Jason C JC Schoellerman Jeff J Lord Brian B Coe Kevin J KJ Carruthers Nicholas I NI Nguyen Leslie L Jiang Xiaohui X Koudriakova Tatiana T Balana Bartosz B Letavic Michael A MA

ACS medicinal chemistry letters 20190110 3

Herein, we disclose a series of selective GluN2B negative allosteric modulators containing a 1H-pyrrolo[3,2-b]pyridine core. Lead optimization efforts included increasing brain penetration as well as decreasing cytochrome P450 inhibition and hERG channel binding. The series was also optimized to reduce metabolic turnover in human and rat. Compounds 9, 25, 30, and 34 have good in vitro GluN2B potency and good predicted absorption, but moderate to high pro ...[more]

PMID: 30891123

Similar Datasets

Mapping the binding of GluN2B-selective N-methyl-D-aspartate receptor negative allosteric modulators.

Project description:We have used recent structural advances in our understanding of the N-methyl-d-aspartate (NMDA) receptor amino terminal domain to explore the binding mode of multiple diaryl GluN2B-selective negative allosteric modulators at the interface between the GluN1 and GluN2B amino-terminal domains. We found that interaction of the A ring within the binding pocket seems largely invariant for a variety of structurally distinct ligands. In addition, a range of structurally diverse linkers between the two aryl rings can be accommodated by the binding site, providing a potential opportunity to tune interactions with the ligand binding pocket via changes in hydrogen bond donors, acceptors, as well as stereochemistry. The most diversity in atomic interactions between protein and ligand occur in the B ring, with functional groups that contain electron donors and acceptors providing additional atomic contacts within the pocket. A cluster of residues distant to the binding site also control ligand potency, the degree of inhibition, and show ligand-induced increases in motion during molecular dynamics simulations. Mutations at some of these residues seem to distinguish between structurally distinct ligands and raise the possibility that GluN2B-selective ligands can be divided into multiple classes. These results should help facilitate the development of well tolerated GluN2B subunit-selective antagonists.

| S-EPMC3400845 | biostudies-literature

5-Bromo-1H-pyrrolo-[2,3-b]pyridine.

Project description:In the title compound, C7H5BrN2, fused six-membered pyridine and five-membered pyrrole rings form the essentially planar aza-indole skeleton (r.m.s. deviation = 0.017?Å). In the crystal, pairs of N-H?N hydrogen bonds connect the mol-ecules into inversion dimers.

| S-EPMC3588463 | biostudies-literature

Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1).

Project description:The protein kinase MPS1 is a crucial component of the spindle assembly checkpoint signal and is aberrantly overexpressed in many human cancers. MPS1 is one of the top 25 genes overexpressed in tumors with chromosomal instability and aneuploidy. PTEN-deficient breast tumor cells are particularly dependent upon MPS1 for their survival, making it a target of significant interest in oncology. We report the discovery and optimization of potent and selective MPS1 inhibitors based on the 1H-pyrrolo[3,2-c]pyridine scaffold, guided by structure-based design and cellular characterization of MPS1 inhibition, leading to 65 (CCT251455). This potent and selective chemical tool stabilizes an inactive conformation of MPS1 with the activation loop ordered in a manner incompatible with ATP and substrate-peptide binding; it displays a favorable oral pharmacokinetic profile, shows dose-dependent inhibition of MPS1 in an HCT116 human tumor xenograft model, and is an attractive tool compound to elucidate further the therapeutic potential of MPS1 inhibition.

| S-EPMC3873811 | biostudies-literature

2-(1H-Pyrrolo-[2,3-b]pyridin-2-yl)pyridine.

Project description:In the title compound, C(12)H(9)N(3), the dihedral angle between the pyridine and aza-indole rings is 6.20 (2)°. In the crystal, pairs of N-H⋯N hydrogen bonds link mol-ecules into inversion dimers.

| S-EPMC3379496 | biostudies-literature

Bioresearch of New 1H-pyrrolo[3,4-c]pyridine-1,3(2H)-diones.

Project description:The subject of the work was the synthesis of new derivatives of1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione with potential analgesic and sedative activity. Eight compounds werereceived. The analgesic activity of the new compounds was confirmed in the "hot plate" test and in the "writhing" test. All tested imides 8-15 were more active in the "writhing" test than aspirin, and two of them, 9 and 11, were similar to morphine. In addition, all of the new imides inhibited the locomotor activity in mice to a statistically significant extent, and two of them also prolonged the duration of thiopental sleep.On the basis of the results obtained for the previously synthesized imides and the results presented in this paper, an attempt was madeto determine the relationship between thechemical structure of imides and their analgesic and sedativeproperties.

| S-EPMC7764601 | biostudies-literature

Subtype-selective mechanisms of negative allosteric modulators binding to group I metabotropic glutamate receptors.

Project description:Group I metabotropic glutamate receptors (mGlu1 and mGlu5) are promising targets for multiple psychiatric and neurodegenerative disorders. Understanding the subtype selectivity of mGlu1 and mGlu5 allosteric sites is essential for the rational design of novel modulators with single- or dual-target mechanism of action. In this study, starting from the deposited mGlu1 and mGlu5 crystal structures, we utilized computational modeling approaches integrating docking, molecular dynamics simulation, and efficient post-trajectory analysis to reveal the subtype-selective mechanism of mGlu1 and mGlu5 to 10 diverse drug scaffolds representing known negative allosteric modulators (NAMs) in the literature. The results of modeling identified six pairs of non-conserved residues and four pairs of conserved ones as critical features to distinguish the selective NAMs binding to the corresponding receptors. In addition, nine pairs of residues are beneficial to the development of novel dual-target NAMs of group I metabotropic glutamate receptors. Furthermore, the binding modes of a reported dual-target NAM (VU0467558) in mGlu1 and mGlu5 were predicted to verify the identified residues that play key roles in the receptor selectivity and the dual-target binding. The results of this study can guide rational structure-based design of novel NAMs, and the approach can be generally applicable to characterize the features of selectivity for other G-protein-coupled receptors.

| S-EPMC8285414 | biostudies-literature

2-(4-Methoxy-phen-yl)-6-trifluoro-methyl-1H-pyrrolo[3,2-c]quinoline monohydrate.

Project description:In the title compound, C(19)H(13)F(3)N(2)O·H(2)O, the phenyl and pyrroloquinoline ring system are close to coplanar [dihedral angle = 10.94?(4)°]. The meth-oxy group also is almost coplanar with the phenyl ring [5.4?(1)°]. In the crystal structure N-H?O(water) and water-quinoline O-H?N hydrogen bonds build up a supra-molecular chain-like arrangement along [001]. The remaining H atom of the water mol-ecule does not take part in classical hydrogen bonds. Instead, this O-H bond points toward the center of the phenyl ring of a neighbouring mol-ecule. Weak C-H?O and C-H?? inter-actions are also present.

| S-EPMC2979020 | biostudies-literature

4-(1H-Pyrrolo-[2,3-b]pyridin-2-yl)pyridine.

Project description:The asymmetric unit of the title compound, C12H9N3, contains two independent mol-ecules in which the dihedral angle between the pyridine and aza-indole rings are 8.23?(6) and 9.89?(2)°. In the crystal, both types of mol-ecule are connected by pairs of N-H-N hydrogen bonds into inversion dimers.

| S-EPMC3647869 | biostudies-other

Pyrrolo[3,2-c]pyridine derivatives with potential inhibitory effect against FMS kinase: in vitro biological studies.

Project description:A series of eighteen pyrrolo[3,2-c]pyridine derivatives were tested for inhibitory effect against FMS kinase. Compounds 1e and 1r were the most potent among all the other tested analogues (IC50?=?60?nM and 30?nM, respectively). They were 1.6 and 3.2 times, respectively, more potent than our lead compound, KIST101029 (IC50?=?96?nM). Compound 1r was tested over a panel of 40 kinases including FMS, and exerted selectivity against FMS kinase. It was further tested against bone marrow-derived macrophages (BMDM) and its IC50 was 84?nM (2.32-fold more potent than KIST101029 (IC50?=?195?nM)). Compound 1r was also tested for antiproliferative activity against a panel of six ovarian, two prostate, and five breast cancer cell lines, and its IC50 values ranged from 0.15-1.78?µM. It possesses also the merit of selectivity towards cancer cells than normal fibroblasts.

| S-EPMC6084503 | biostudies-literature

4-Chloro-1-(4-methyl-phenyl-sulfon-yl)-1H-pyrrolo[2,3-b]pyridine.

Project description:The crystal structure of the title compound, C(14)H(11)ClN(2)O(2)S, features a three-dimensional network stabilized by ?-? inter-actions between the rings of the 4-methyl-phenyl-sulfonyl protecting group [centroid-centroid distance = 3.623?(1)?Å]. The 4-methyl-phenyl-sulfonyl ring makes a dihedral angle of 79.60?(6)° with the 4-chloro-1H-pyrrolo[2,3-b]pyridine unit.

| S-EPMC2972132 | biostudies-literature